Compare BFS & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BFS | VIR |
|---|---|---|
| Founded | 1993 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 759.2M | 825.0M |
| IPO Year | 1993 | 2019 |
| Metric | BFS | VIR |
|---|---|---|
| Price | $31.55 | $6.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $25.73 |
| AVG Volume (30 Days) | 75.0K | ★ 2.0M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | ★ 7.48% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $282,618,000.00 | $16,860,000.00 |
| Revenue This Year | $8.14 | N/A |
| Revenue Next Year | $5.75 | $46.25 |
| P/E Ratio | $27.66 | ★ N/A |
| Revenue Growth | ★ 5.61 | N/A |
| 52 Week Low | $29.16 | $4.16 |
| 52 Week High | $39.15 | $14.45 |
| Indicator | BFS | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 54.81 | 48.14 |
| Support Level | $31.00 | $5.73 |
| Resistance Level | $31.60 | $6.16 |
| Average True Range (ATR) | 0.58 | 0.36 |
| MACD | -0.00 | -0.08 |
| Stochastic Oscillator | 62.50 | 22.93 |
Saul Centers Inc is a self-managed real estate investment trust which invests in, operates and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: shopping centers, which contribute the maximum portion of total revenue; and mixed-use properties. Maximum tenants include grocery stores, discount department stores, and drug stores.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.